

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF ELIGIBLE PROBAND
ALL CLINICS - FINAL PHASE 1 GOKIND - DATA AS OF 18APR06

CHARACTERISTIC	STATISTICS/ CATEGORIES	CASE			CONTROL		
		TRIO	SINGLETON	TOTAL	TRIO	SINGLETON	TOTAL
N=:		271	664	935	322	622	944
RASS Patient N=:		0	0	0	15	30	45
SEX (%):	male	117 (43.2 %)	351 (52.9 %)	468 (50.1 %)	131 (40.7 %)	252 (40.5 %)	383 (40.6 %)
AGE AT ENTRY:	n	271	664	935	322	622	944
	mean (std)	39.9 (7.2)	43.8 (6.8)	42.6 (7.2)	34.8 (8.2)	39.8 (8.4)	38.1 (8.6)
	minimum	20.0	22.0	20.0	18.0	19.0	18.0
	25th-percentile	35.0	40.0	38.0	28.0	34.0	31.0
	median	39.0	44.0	43.0	35.0	41.0	39.0
	75th-percentile	45.0	49.0	48.0	41.0	46.0	45.0
	maximum	55.0	59.0	59.0	53.0	55.0	55.0
RACE:	white	257 (94.8 %)	578 (87.0 %)	835 (89.3 %)	313 (97.2 %)	599 (96.3 %)	912 (96.6 %)
	black	2 (0.7 %)	35 (5.3 %)	37 (4.0 %)	1 (0.3 %)	7 (1.1 %)	8 (0.8 %)
	hispanic	11 (4.1 %)	35 (5.3 %)	46 (4.9 %)	3 (0.9 %)	3 (0.5 %)	6 (0.6 %)
	american indian/alas	0 (0.0 %)	6 (0.9 %)	6 (0.6 %)	1 (0.3 %)	1 (0.2 %)	2 (0.2 %)
	other	1 (0.4 %)	7 (1.1 %)	8 (0.9 %)	2 (0.6 %)	8 (1.3 %)	10 (1.1 %)
	missing	0 (0.0 %)	3 (0.5 %)	3 (0.3 %)	2 (0.6 %)	4 (0.6 %)	6 (0.6 %)
DURATION of DIABETES (yrs):	n	271	664	935	322	622	944
	mean (std)	29.4 (7.4)	31.3 (8.1)	30.8 (7.9)	23.6 (7.1)	26.1 (7.8)	25.3 (7.7)
	minimum	11.0	10.0	10.0	15.0	15.0	15.0
	25th-percentile	24.0	25.0	25.0	18.0	20.0	19.0
	median	29.0	32.0	31.0	22.0	25.0	24.0
	75th-percentile	35.0	37.0	36.0	28.0	32.0	31.0
	maximum	50.0	54.0	54.0	47.0	52.0	52.0

SINGLETON includes SINGLETONs and INCOMPLETE TRIOs.

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF ELIGIBLE PROBAND
ALL CLINICS - FINAL PHASE 1 GOKIND - DATA AS OF 18APR06

CHARACTERISTIC	STATISTICS/ CATEGORIES	CASE			CONTROL		
		TRIO	SINGLETON	TOTAL	TRIO	SINGLETON	TOTAL
NOW ON INSULIN(NON-PANCR. TRANS.):	no	0 (0.0 %)	1 (0.2 %)	1 (0.2 %)	0 (0.0 %)	0 (0.0 %)	
	yes	205 (100.0 %)	419 (99.8 %)	624 (99.8 %)	322 (100.0 %)	622 (100.0 %)	944 (100.0 %)
INSUL. REGIMEN(NON-PANCR. TRANS.):	<2 Shots	10 (4.9 %)	31 (7.4 %)	41 (6.6 %)	14 (4.3 %)	32 (5.1 %)	46 (4.9 %)
	MDI	137 (66.8 %)	283 (67.4 %)	420 (67.2 %)	154 (47.8 %)	353 (56.8 %)	507 (53.7 %)
	pump	55 (26.8 %)	97 (23.1 %)	152 (24.3 %)	148 (46.0 %)	220 (35.4 %)	368 (39.0 %)
	missing	3 (1.5 %)	9 (2.1 %)	12 (1.9 %)	6 (1.9 %)	17 (2.7 %)	23 (2.4 %)
INSULIN DOSAGE(units/kg/day):	n	249	595	844	307	598	905
	mean (std)	0.5 (0.3)	0.5 (0.3)	0.5 (0.3)	0.6 (0.2)	0.6 (0.2)	0.6 (0.2)
	minimum	0.0	0.0	0.0	0.1	0.0	0.0
	25th-percentile	0.4	0.3	0.3	0.5	0.4	0.4
	median	0.6	0.5	0.5	0.6	0.5	0.6
	75th-percentile	0.7	0.7	0.7	0.7	0.7	0.7
FOCAL LASER TREATMENT:	no	227 (83.8 %)	535 (80.6 %)	762 (81.5 %)	316 (98.1 %)	603 (96.9 %)	919 (97.4 %)
	yes	23 (8.5 %)	70 (10.5 %)	93 (9.9 %)	3 (0.9 %)	13 (2.1 %)	16 (1.7 %)
	unknown	19 (7.0 %)	53 (8.0 %)	72 (7.7 %)	2 (0.6 %)	3 (0.5 %)	5 (0.5 %)
	missing	2 (0.7 %)	6 (0.9 %)	8 (0.9 %)	1 (0.3 %)	3 (0.5 %)	4 (0.4 %)
PAN-RETINAL LASER TREATMENT:	no	48 (17.7 %)	94 (14.2 %)	142 (15.2 %)	274 (85.1 %)	507 (81.5 %)	781 (82.7 %)
	yes	215 (79.3 %)	544 (81.9 %)	759 (81.2 %)	43 (13.4 %)	105 (16.9 %)	148 (15.7 %)
	unknown	7 (2.6 %)	19 (2.9 %)	26 (2.8 %)	3 (0.9 %)	5 (0.8 %)	8 (0.8 %)
	missing	1 (0.4 %)	7 (1.1 %)	8 (0.9 %)	2 (0.6 %)	5 (0.8 %)	7 (0.7 %)
ESRD:	no	123 (45.4 %)	203 (30.6 %)	326 (34.9 %)	322 (100.0 %)	622 (100.0 %)	944 (100.0 %)
	yes	148 (54.6 %)	461 (69.4 %)	609 (65.1 %)	0 (0.0 %)	0 (0.0 %)	

SINGLETON includes SINGLETONs and INCOMPLETE TRIOs.

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF ELIGIBLE PROBAND
ALL CLINICS - FINAL PHASE 1 GOKIND - DATA AS OF 18APR06

		CASE			CONTROL		
CHARACTERISTIC	STATISTICS/ CATEGORIES	TRIO	SINGLETON	TOTAL	TRIO	SINGLETON	TOTAL
ACR/AER1 (ug/mg) (NON_ESRD ONLY):	n	107	166	273	266	544	810
	mean (std)	1383.7 (1401)	1430.2 (1280)	1411.9 (1326)	7.2 (4.8)	6.7 (4.3)	6.9 (4.5)
	minimum	8.6	3.9	3.9	0.0	0.0	0.0
	25th-percentile	483.1	535.4	521.7	3.9	3.9	3.9
	median	857.6	1102.7	943.9	5.8	5.7	5.7
	75th-percentile	1652.0	1676.5	1652.0	9.0	8.8	8.9
	maximum	8714.3	7087.7	8714.3	27.1	35.2	35.2
ACR/AER2 (ug/mg) (NON_ESRD ONLY):	n	123	202	325	322	622	944
	mean (std)	1625.3 (1551)	1655.7 (2017)	1644.2 (1852)	6.8 (5.7)	6.8 (4.8)	6.8 (5.1)
	minimum	74.6	76.2	74.6	1.2	0.6	0.6
	25th-percentile	535.7	504.7	510.6	3.4	3.6	3.6
	median	1065.2	1051.8	1058.4	5.1	5.5	5.3
	75th-percentile	2172.1	1848.8	1958.4	7.8	8.2	8.1
	maximum	8431.4	15969.7	15969.7	37.5	38.3	38.3
ACR/AER3 (ug/mg) (NON_ESRD ONLY):	n	10	30	40	26	31	57
	mean (std)	1289.9 (935.1)	1362.4 (3405)	1344.2 (2971)	6.7 (4.0)	9.3 (6.8)	8.1 (5.8)
	minimum	308.7	188.5	188.5	1.5	1.1	1.1
	25th-percentile	662.6	402.1	424.3	4.1	3.7	4.0
	median	939.9	557.0	660.3	5.4	6.7	6.3
	75th-percentile	1838.0	938.8	970.6	9.2	15.9	11.9
	maximum	2940.0	19102.0	19102.0	16.9	30.6	30.6
CARDIOVASCULAR COMPLICATION:	no	52 (19.2 %)	83 (12.5 %)	135 (14.4 %)	293 (91.0 %)	564 (90.7 %)	857 (90.8 %)
	yes	219 (80.8 %)	581 (87.5 %)	800 (85.6 %)	29 (9.0 %)	58 (9.3 %)	87 (9.2 %)

SINGLETON includes SINGLETONs and INCOMPLETE TRIOs.

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF ELIGIBLE PROBAND
ALL CLINICS - FINAL PHASE 1 GOKIND - DATA AS OF 18APR06

CHARACTERISTIC	STATISTICS/ CATEGORIES	CASE			CONTROL		
		TRIO	SINGLETON	TOTAL	TRIO	SINGLETON	TOTAL
HYPERTENSIVE:	no	47 (17.3 %)	97 (14.6 %)	144 (15.4 %)	305 (94.7 %)	574 (92.3 %)	879 (93.1 %)
	yes	224 (82.7 %)	567 (85.4 %)	791 (84.6 %)	13 (4.0 %)	44 (7.1 %)	57 (6.0 %)
	unknown	0 (0.0 %)	0 (0.0 %)		1 (0.3 %)	1 (0.2 %)	2 (0.2 %)
	missing	0 (0.0 %)	0 (0.0 %)		3 (0.9 %)	3 (0.5 %)	6 (0.6 %)
NEUROPATHY DUE TO DIABETES:	no	94 (34.7 %)	197 (29.7 %)	291 (31.1 %)	292 (90.7 %)	536 (86.2 %)	828 (87.7 %)
	yes	173 (63.8 %)	462 (69.6 %)	635 (67.9 %)	26 (8.1 %)	79 (12.7 %)	105 (11.1 %)
	unknown	4 (1.5 %)	5 (0.8 %)	9 (1.0 %)	4 (1.2 %)	7 (1.1 %)	11 (1.2 %)
PERIPHERAL VASCULAR COMPLICATION:	no	196 (72.3 %)	381 (57.4 %)	577 (61.7 %)	314 (97.5 %)	603 (96.9 %)	917 (97.1 %)
	yes	75 (27.7 %)	280 (42.2 %)	355 (38.0 %)	7 (2.2 %)	14 (2.3 %)	21 (2.2 %)
	unknown	0 (0.0 %)	3 (0.5 %)	3 (0.3 %)	1 (0.3 %)	5 (0.8 %)	6 (0.6 %)
GANGRENE:	no	255 (94.1 %)	605 (91.1 %)	860 (92.0 %)	321 (99.7 %)	615 (98.9 %)	936 (99.2 %)
	yes	16 (5.9 %)	53 (8.0 %)	69 (7.4 %)	0 (0.0 %)	2 (0.3 %)	2 (0.2 %)
	unknown	0 (0.0 %)	3 (0.5 %)	3 (0.3 %)	0 (0.0 %)	0 (0.0 %)	
	missing	0 (0.0 %)	3 (0.5 %)	3 (0.3 %)	1 (0.3 %)	5 (0.8 %)	6 (0.6 %)
NON-TRAUMATIC AMPUTATION:	no	246 (90.8 %)	552 (83.1 %)	798 (85.3 %)	321 (99.7 %)	614 (98.7 %)	935 (99.0 %)
	yes	25 (9.2 %)	108 (16.3 %)	133 (14.2 %)	0 (0.0 %)	3 (0.5 %)	3 (0.3 %)
	unknown	0 (0.0 %)	1 (0.2 %)	1 (0.1 %)	0 (0.0 %)	0 (0.0 %)	
	missing	0 (0.0 %)	3 (0.5 %)	3 (0.3 %)	1 (0.3 %)	5 (0.8 %)	6 (0.6 %)
AUTO-IMMUNE DISEASE:	No	234 (86.3 %)	496 (74.7 %)	730 (78.1 %)	247 (76.7 %)	494 (79.4 %)	741 (78.5 %)
	Yes (with 1 disease)	30 (11.1 %)	135 (20.3 %)	165 (17.6 %)	66 (20.5 %)	110 (17.7 %)	176 (18.6 %)
	Yes (with >1 disease)	7 (2.6 %)	33 (5.0 %)	40 (4.3 %)	9 (2.8 %)	18 (2.9 %)	27 (2.9 %)
EVER SMOKED:	no	147 (54.2 %)	339 (51.1 %)	486 (52.0 %)	221 (68.6 %)	410 (65.9 %)	631 (66.8 %)
	yes	124 (45.8 %)	325 (48.9 %)	449 (48.0 %)	100 (31.1 %)	208 (33.4 %)	308 (32.6 %)
	unknown	0 (0.0 %)	0 (0.0 %)		1 (0.3 %)	4 (0.6 %)	5 (0.5 %)

SINGLETON includes SINGLETONs and INCOMPLETE TRIOs.

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF ELIGIBLE PROBAND
ALL CLINICS - FINAL PHASE 1 GOKIND - DATA AS OF 18APR06

CHARACTERISTIC	STATISTICS/ CATEGORIES	CASE			CONTROL		
		TRIO	SINGLETON	TOTAL	TRIO	SINGLETON	TOTAL
CURRENT SMOKER:	no	227 (83.8 %)	564 (84.9 %)	791 (84.6 %)	286 (88.8 %)	549 (88.3 %)	835 (88.5 %)
	yes	43 (15.9 %)	100 (15.1 %)	143 (15.3 %)	35 (10.9 %)	65 (10.5 %)	100 (10.6 %)
	unknown	0 (0.0 %)	0 (0.0 %)		0 (0.0 %)	1 (0.2 %)	1 (0.1 %)
	missing	1 (0.4 %)	0 (0.0 %)	1 (0.1 %)	1 (0.3 %)	7 (1.1 %)	8 (0.8 %)
SYSTOLIC BP (mm Hg):	n	267	652	919	308	611	919
	mean (std)	129.7 (18.0)	132.0 (19.2)	131.3 (18.9)	115.8 (11.4)	118.5 (12.2)	117.6 (12.0)
	minimum	79.5	51.0	51.0	86.0	83.0	83.0
	25th-percentile	119.0	120.0	120.0	108.0	110.0	110.0
	median	128.5	131.0	130.0	116.3	118.0	118.0
	75th-percentile	142.0	143.3	143.0	122.5	126.0	125.0
	maximum	192.0	206.0	206.0	168.0	178.0	178.0
DIASTOLIC BP (mm Hg):	n	267	652	919	308	611	919
	mean (std)	74.9 (10.8)	74.2 (11.0)	74.4 (10.9)	71.3 (7.9)	71.4 (8.0)	71.4 (7.9)
	minimum	40.0	40.0	40.0	50.0	48.5	48.5
	25th-percentile	69.0	68.0	68.0	66.0	67.0	66.5
	median	76.0	73.0	74.0	70.0	70.0	70.0
	75th-percentile	82.0	81.0	81.0	78.0	77.0	77.0
	maximum	102.0	130.0	130.0	94.0	98.0	98.0
BODY MASS INDEX (kg/m2):	n	267	647	914	308	609	917
	mean (std)	25.5 (5.2)	25.8 (5.4)	25.7 (5.3)	26.4 (4.5)	26.1 (4.3)	26.2 (4.4)
	minimum	16.5	15.1	15.1	18.1	18.1	18.1
	25th-percentile	21.4	22.0	21.8	23.3	23.1	23.2
	median	24.3	24.8	24.7	25.2	25.1	25.2
	75th-percentile	28.2	28.2	28.2	28.5	28.2	28.3
	maximum	47.7	48.1	48.1	49.2	47.7	49.2

SINGLETON includes SINGLETONs and INCOMPLETE TRIOs.

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF ELIGIBLE PROBAND
ALL CLINICS - FINAL PHASE 1 GOKIND - DATA AS OF 18APR06

		CASE			CONTROL			
CHARACTERISTIC	STATISTICS/ CATEGORIES	TRIO	SINGLETON	TOTAL	TRIO	SINGLETON	TOTAL	
ABNORMAL SERUM CREATININE:	no	131 (48.3 %)	280 (42.2 %)	411 (44.0 %)	321 (99.7 %)	618 (99.4 %)	939 (99.5 %)	
	yes	140 (51.7 %)	384 (57.8 %)	524 (56.0 %)	1 (0.3 %)	4 (0.6 %)	5 (0.5 %)	
NATURAL WAIST CIRCUM. (cm):	n	89	333	422	142	236	378	
	mean (std)	88.6 (14.5)	89.4 (15.1)	89.3 (15.0)	84.0 (12.4)	86.9 (13.8)	85.8 (13.4)	
	minimum	63.7	63.8	63.7	39.5	63.4	39.5	
	25th-percentile	77.5	79.7	78.9	75.0	76.2	75.9	
	median	87.0	86.8	87.0	83.6	85.3	84.4	
	75th-percentile	98.8	97.0	97.1	90.7	95.5	93.6	
	maximum	133.8	150.0	150.0	120.9	174.0	174.0	
	GFR(Cockcroft-Gault)(ml/min):	n	236	624	860	303	599	902
	mean (std)	63.2 (33.6)	61.1 (32.4)	61.7 (32.7)	113.6 (30.1)	109.1 (31.3)	110.6 (30.9)	
	minimum	7.0	6.4	6.4	43.1	52.3	43.1	
	25th-percentile	39.3	38.6	38.7	91.2	87.8	89.0	
	median	57.6	57.1	57.3	112.4	104.6	107.1	
	75th-percentile	83.7	81.8	82.0	129.7	125.4	126.9	
	maximum	250.0	174.2	250.0	314.7	405.3	405.3	
HBA1C (%):	n	268	644	912	319	620	939	
		mean (std)	7.8 (2.0)	7.4 (1.9)	7.5 (2.0)	7.6 (1.2)	7.5 (1.1)	7.5 (1.2)
		minimum	4.1	3.0	3.0	5.1	4.8	4.8
		25th-percentile	6.1	5.7	5.8	6.7	6.7	6.7
		median	7.7	7.3	7.4	7.5	7.3	7.3
		75th-percentile	9.1	8.7	8.8	8.1	8.1	8.1
		maximum	14.0	13.4	14.0	13.0	12.3	13.0

SINGLETON includes SINGLETONs and INCOMPLETE TRIOs.

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF ELIGIBLE PROBAND
ALL CLINICS - FINAL PHASE 1 GOKIND - DATA AS OF 18APR06

		CASE			CONTROL		
CHARACTERISTIC	STATISTICS/ CATEGORIES	TRIO	SINGLETON	TOTAL	TRIO	SINGLETON	TOTAL
TOTAL CHOLESTEROL (mg/dL):	n	238	630	868	300	574	874
	mean (std)	196.8 (44.5)	187.0 (46.0)	189.7 (45.8)	185.5 (33.5)	185.0 (31.4)	185.2 (32.1)
	minimum	98.0	63.0	63.0	101.0	111.0	101.0
	25th-percentile	168.0	157.0	160.0	163.5	164.0	164.0
	median	193.0	184.0	187.5	183.0	181.0	182.0
	75th-percentile	224.0	209.0	212.5	206.0	202.0	203.0
	maximum	385.0	472.0	472.0	301.0	311.0	311.0
HDL (mg/dL):	n	238	629	867	300	573	873
	mean (std)	55.4 (16.8)	53.6 (17.5)	54.1 (17.3)	56.6 (14.6)	59.0 (15.8)	58.1 (15.4)
	minimum	24.0	20.0	20.0	25.0	25.0	25.0
	25th-percentile	43.0	42.0	42.0	46.0	48.0	47.0
	median	52.0	51.0	51.0	54.5	57.0	57.0
	75th-percentile	67.0	63.0	63.0	66.0	68.0	67.0
	maximum	118.0	138.0	138.0	101.0	105.0	105.0
SERUM CREATININE (mg/dL):	n	237	630	867	314	604	918
	mean (std)	2.0 (1.5)	2.2 (2.0)	2.1 (1.9)	0.9 (0.1)	0.9 (0.2)	0.9 (0.2)
	minimum	0.7	0.5	0.5	0.6	0.4	0.4
	25th-percentile	1.2	1.2	1.2	0.8	0.8	0.8
	median	1.5	1.5	1.5	0.9	0.9	0.9
	75th-percentile	2.1	2.2	2.2	1.0	1.0	1.0
	maximum	11.3	15.5	15.5	1.4	1.6	1.6

SINGLETON includes SINGLETONs and INCOMPLETE TRIOs.

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF ELIGIBLE PROBAND
ALL CLINICS - FINAL PHASE 1 GOKIND - DATA AS OF 18APR06

		CASE			CONTROL		
CHARACTERISTIC	STATISTICS/ CATEGORIES	TRIO	SINGLETON	TOTAL	TRIO	SINGLETON	TOTAL
SERUM CYSTATIN (mg/L):	n	231	618	849	289	571	860
	mean (std)	2.1 (1.3)	2.3 (1.8)	2.3 (1.7)	0.8 (0.1)	0.8 (0.1)	0.8 (0.1)
	minimum	0.6	0.5	0.5	0.4	0.5	0.4
	25th-percentile	1.3	1.3	1.3	0.7	0.7	0.7
	median	1.7	1.7	1.7	0.8	0.8	0.8
	75th-percentile	2.6	2.5	2.5	0.9	0.9	0.9
	maximum	9.5	12.0	12.0	1.2	1.8	1.8
TAKING LIPID LOWERING MEDICATION:	no	159 (58.7 %)	353 (53.2 %)	512 (54.8 %)	266 (82.6 %)	525 (84.4 %)	791 (83.8 %)
	yes	112 (41.3 %)	310 (46.7 %)	422 (45.1 %)	50 (15.5 %)	90 (14.5 %)	140 (14.8 %)
	missing	0 (0.0 %)	1 (0.2 %)	1 (0.1 %)	6 (1.9 %)	7 (1.1 %)	13 (1.4 %)
TAKING ACE INHIBITORS:	no	120 (44.3 %)	340 (51.2 %)	460 (49.2 %)	307 (95.3 %)	596 (95.8 %)	903 (95.7 %)
	yes	148 (54.6 %)	319 (48.0 %)	467 (49.9 %)	0 (0.0 %)	0 (0.0 %)	
	missing	3 (1.1 %)	5 (0.8 %)	8 (0.9 %)	15 (4.7 %)	26 (4.2 %)	41 (4.3 %)
TAKING ANTI-HYPERTENSIVE DRUGS:	no	122 (45.0 %)	238 (35.8 %)	360 (38.5 %)	308 (95.7 %)	591 (95.0 %)	899 (95.2 %)
	yes	146 (53.9 %)	415 (62.5 %)	561 (60.0 %)	0 (0.0 %)	0 (0.0 %)	
	missing	3 (1.1 %)	11 (1.7 %)	14 (1.5 %)	14 (4.3 %)	31 (5.0 %)	45 (4.8 %)
TIME TO EVENT:	n	148	459	607	0	0	0
	mean (std)	24.9 (6.9)	24.9 (7.2)	24.9 (7.1)	. (.)	. (.)	. (.)
	minimum	13.0	9.0	9.0	.	.	.
	25th-percentile	20.0	19.0	19.0	.	.	.
	median	24.0	24.0	24.0	.	.	.
	75th-percentile	29.0	30.0	30.0	.	.	.
	maximum	46.0	51.0	51.0	.	.	.

SINGLETON includes SINGLETONs and INCOMPLETE TRIOs.

GOKIND STUDY
SUMMARY OF CLINICAL AND BIOCHEMICAL CHARACTERISTICS OF ELIGIBLE PROBAND
ALL CLINICS - FINAL PHASE 1 GOKIND - DATA AS OF 18APR06

		CASE			CONTROL		
CHARACTERISTIC	STATISTICS/ CATEGORIES	TRIO	SINGLETON	TOTAL	TRIO	SINGLETON	TOTAL
PANCREAS TRANSPLANT:	no	205 (75.6 %)	419 (63.1 %)	624 (66.7 %)	320 (99.4 %)	621 (99.8 %)	941 (99.7 %)
	yes	66 (24.4 %)	244 (36.7 %)	310 (33.2 %)	0 (0.0 %)	0 (0.0 %)	
	missing	0 (0.0 %)	1 (0.2 %)	1 (0.1 %)	2 (0.6 %)	1 (0.2 %)	3 (0.3 %)
RENAL FUNCTION STATUS:	CONTROL	0 (0.0 %)	0 (0.0 %)		322 (100.0 %)	622 (100.0 %)	944 (100.0 %)
	PROTEINURIC	123 (45.4 %)	203 (30.6 %)	326 (34.9 %)	0 (0.0 %)	0 (0.0 %)	
	DIALYSIS	11 (4.1 %)	42 (6.3 %)	53 (5.7 %)	0 (0.0 %)	0 (0.0 %)	
	TRANSPLANT	137 (50.6 %)	419 (63.1 %)	556 (59.5 %)	0 (0.0 %)	0 (0.0 %)	

SINGLETON includes SINGLETONs and INCOMPLETE TRIOs.